June 13, 2026 -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma ecosystem with Europe, today announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123M (€106M). Following its initial launch in December 2025, the fund has secured backing from a syndicate of prominent institutional investors—including lead investor Hellenic Development Bank of Investments (HDBI)—and global family offices.

Financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors Proceeds will support clinical advancement of lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closin

– ETHY-001 targets the causal pathogenic mechanism underlying both conditions – – Patient-friendly subcutaneous administration with half-life extension for infrequent dosing – – First-in-human clinical trial expected to initiate in the second half of 2026 – – Preclinical data to be presented in an oral presentation at ENDO on June 15, 2026 – – Backed by leading healthcare investors including Atlas Venture, Medicxi Ventures, Avoro Capital, Nandi Life Sciences, and Checkpoint Capital – June 10, 2

Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, today announced the closing of a $6 million financing round led by VCapital, with participation from Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis. In addition to the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program in animal health. T

Roche is wagering billions of dollars on a medicine that trashes a troublesome protein instead of stifling its activity. The Swiss drugmaker on Monday reached a deal with Nurix Therapeutics to codevelop a therapy called bexobrutideg that’s nearing late-stage testing. Roche will pay Nurix $700 million up front and, in return, will split U.S. rights to the drug while gaining full ownership elsewhere. Roche will also cover 60% of the development costs and hand Nurix royalties on non-U.S. sales. N

Gilead Sciences (Nasdaq: GILD) and Belgium-based Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) have completed the joint acquisition of Ouro Medicines in a deal valued at up to USD 2.175 billion. The transaction centers on gamgertamig (OM336; CM-336), a clinical-stage BCMAxCD3 bispecific T cell engager under development for auto-immune diseaes, originally licensed from China’s Keymed Biosciences. Gilead is taking commercial rights to the molecule outside Greater China, while Lakefront as

The company is expecting to spend $150 million to develop its Wnt/β-catenin pathway inhibitor zolucatetide for desmoid tumors. Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect. The Massachusetts biotech, formerly known as FogPharma, announced plans last month to list on the Nasdaq, and has now put some figures behind that ambition. Parabilis reckons it can offer 25 million shares pr

Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A financing from RA Capital Management, LP (“RA Capital”), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital was the sole investor in the financing. The Series A financing will support comp

June 2, 2026 -- Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing investor Tau Capital. The proceeds will be used to advance Tavo's pipeline of innovative therapies targeting glaucoma and retinal disease. In conjunction with the financing, Tavo Biotherapeutics also announced the appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer, t

Anthropic has raised $65 billion in Series H funding, bringing its post-money valuation to $965 billion and surpassing OpenAI to become the world's highest-valued private AI company. Altimeter Capital, Dragoneer, Greenoaks, Sequoia Capital, Capital Group, Coatue, D1 Capital Partners, GIC, ICONIQ and XN co-led the round. Other investors in the round include AMP PBC, Baillie Gifford, Blackstone, Brookfield, D.E. Shaw Ventures, DST Global, Fidelity Management & Research Company, General Catalyst,